In contrast with our results of VAT-ANGPT2 being downregulated in patients with NAFLD, a study of 93 severely obese subjects found that ANGPT2 expression in VAT was associated with different NAFLD features, including steatosis, ballooning, portal and lobular inflammation [56]. Here, ANGPT2 is linked to metabolic dysfunction-associated steatotic liver disease.